Jordanian firm buys German oncology company for 45 million dollars
dpa German Press Agency
Published: Tuesday January 23, 2007
Amman- Amman-based Hikma Pharmaceuticals has bought the
German oncology sales and marketing company Ribosepharm GmbH from
Ratiopharm GmbH for 45 million dollars, Hikma chairman and CEO Samih
Darwazeh said Tuesday in a statement.
“The acquisition of Ribosepharm provides us with an excellent
platform from which to enter the large and fast-growing oncology
market, which is forecast to become the second largest within the
pharmaceutical industry by 2010,” Darwazeh said.
“Ribosepharm has a strong position in Germany, one of the largest
European oncology markets, and significant distribution capabilities.
We will be able to draw on its experience in the field of oncology
and use its expertise to expand into other oncology markets in
Europe, as well as in the United States, the Middle East and North
Africa (MENA) region,” he added.
Ribosepharm is a well-established and successful oncology company,
specialising in the marketing and distribution of branded generic
injectable oncology products both to private practices and hospitals
in Germany, Darwazeh said.
Since floating on the London Stock Exchange 15 months ago, Hikma
has searched for acquisitions to expand outside the MENA region.
According to company officials, the firm was currently mulling
several other acquisitions, including in the Middle East region and
in firms focusing on the injectables business.
This is an older thread, you may not receive a response, and could
be reviving an old thread. Please consider creating a new thread.
A forum community dedicated to skyscrapers, towers, highrises, construction, and city planning enthusiasts. Come join the discussion about structures, styles, reviews, scale, transportation, skylines, architecture, and more!